| Literature DB >> 31616690 |
Yun Zhang1, Han-Yu Jiang1, Yi Wei1, Bin Song2.
Abstract
BACKGROUND: Sinusoidal obstruction syndrome (SOS) is a kind of rare liver disease which is characterized by damage to small hepatic vessels, affecting particularly the sinusoidal endothelium. Due to the special etiology and high mortality, early diagnosis of SOS is significant for clinical survival and prognosis. AIM: To generalize the common etiologies and clinical symptoms of SOS and summarize the characteristic magnetic resonance imaging (MRI) features so as to provide more valuable information for early diagnosis of SOS.Entities:
Keywords: Ascites; Chemotherapy; Hematopoietic stem cell transplantation; Sinusoidal obstruction syndrome; Tusanqi
Year: 2019 PMID: 31616690 PMCID: PMC6789402 DOI: 10.12998/wjcc.v7.i18.2746
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Figure 1Flowchart of study inclusion.
Quality assessment of 11 case reports
| 1 | Hu et al[ | ** | ** | ** | * | ** |
| 2 | Kang et al[ | ** | ** | ** | ** | ** |
| 3 | Yan[ | ** | ** | ** | * | ** |
| 4 | Yoneda et al[ | ** | * | * | ** | * |
| 5 | Kawa et al[ | ** | * | ** | ** | ** |
| 6 | Mortelé et al[ | ** | ** | * | ** | ** |
| 7 | van den Bosch et al[ | ** | ** | ** | ** | ** |
| 8 | Marasco et al[ | ** | * | * | * | ** |
| 9 | Liu et al[ | ** | * | ** | ** | * |
| 10 | Choi et al[ | ** | * | ** | ** | ** |
| 11 | Arakawa et al[ | ** | * | ** | ** | ** |
*: Quality assessment score.
Quality assessment of 18 case series
| 1 | Chen et al[ | * | ** | * | * | ** | ** |
| 2 | Xu[ | * | ** | * | * | ** | ** |
| 3 | Ye et al[ | * | ** | * | ** | ** | ** |
| 4 | Zheng et al[ | * | ** | * | * | * | ** |
| 5 | Ren et al[ | * | ** | ** | ** | ** | ** |
| 6 | Geng e | * | ** | * | * | * | ** |
| 7 | Chen et al[ | * | ** | * | * | ** | ** |
| 8 | Zhang et al[ | * | ** | * | * | ** | ** |
| 9 | Li et al[ | * | ** | * | ** | ** | ** |
| 10 | Hu et al[ | * | ** | * | * | * | ** |
| 11 | Li et al[ | * | ** | * | * | * | ** |
| 12 | Li et al[ | * | ** | * | ** | * | ** |
| 13 | Yu et al[ | * | ** | * | * | * | ** |
| 14 | Rong[ | * | ** | ** | * | * | ** |
| 15 | Pei et al[ | * | ** | * | * | ** | ** |
| 16 | Zhou et al[ | * | ** | * | * | ** | ** |
| 17 | Guo[ | * | ** | * | * | * | ** |
| 18 | Yang[ | * | ** | ** | ** | * | ** |
*: Quality assessment score.
Characteristic information of patients in 11 case reports
| 1 | Hu et al[ | China | 2014 | 2 | (2/0) | 71/63 | / | Tusanqi | UK | Clinical manifesta-tions + laboratory examination + imaging |
| 2 | Kang et al[ | China | 2015 | 1 | Female | 62 | / | Tusanqi | UK | Biopsy |
| 3 | Yan[ | China | 2015 | 1 | Male | 65 | Liver cirrhosis | Tusanqi (300g) | UK | Clinical manifesta-tions + laboratory examination + imaging |
| 4 | Yoneda et al[ | Japan | 2015 | 1 | Female | 75 | Hepatic metastasis of colonic carcinoma | Preoperative chemotherapy (Pmab + m-FOLFOX6) | 6 cycles (preoperative) + 4.5 month (postopera-tive) | Biopsy |
| 5 | Kawa et al[ | Japan | 2016 | 1 | Female | 40 | Rectal cancer underwent high anterior resection and partial liver resection due to liver metastasis | Oxaliplatin-based chemo-therapy (mFOLFOX6) | 6 mo | Biopsy |
| 6 | Mortelé et al[ | USA | 2001 | 1 | Male | 32 | / | “Poppers”, a recreational drug used during anal intercourse | UK | Biopsy |
| 7 | van den Bosch et al[ | Netherlands | 1999 | 2 | (1/1) | 17/34 | Lymph-ocytic leukemia/acute myeloid leukemia | Bone marrow transplanta-tion | UK | Percuta-neous puncture + histological examination/autopsy |
| 8 | Marasco et al[ | UK | 2016 | 1 | Male | 50 | Ulcerative colitis | 6-thioguanine | UK | Clinical manifesta-tions + imaging |
| 9 | Liu et al[ | China | 2017 | 1 | Male | 52 | Gastric adenocarcinoma | S-1 and oxaliplatine (SOX) regimen | Five cycles | Biopsy |
| 10 | Choi et al[ | Korea | 2016 | 1 | Female | 22 | Laparo-scopic right hemicolectomy for ascending colon cancer | Oxaliplatin-based adjuvant chemo-therapy | Four cycles | Biopsy |
| 11 | Arakawa et al[ | Japan | 2013 | 1 | Female | 40 | Low anterior resection for advanced rectal cancer | Oxaliplatin-based chemo-therapy | Eight cycles | Biopsy |
UK: Unknown.
Characteristic information of patients in 18 case series
| 1 | Chen et al[ | China | 2016 | Retro-spective | 8 | 2006-2013 | 5/3 | 21-67, 42 | / | Tusanqi | 3-18 mo | Biopsy (5) Clinical manifesta-tions + imaging (3) |
| 2 | Xu[ | China | 2015 | Retro-spective | 11 | 2004-2012 | 9/2 | 37-65, 49 | / | Tusanqi (350-800 g) | 15-50 d | Biopsy (2) Clinical manifesta-tions + imaging (9) |
| 3 | Ye et al[ | China | 2015 | Retro-spective | 20 | 2010-2012 | 1/19 | 36-76, 51 | Trauma or stroke | Tusanqi | 10 d-6 mo | Biopsy (12) Clinical manifesta-tions + laboratory examina-tion + imaging (8) |
| 4 | Zheng et al[ | China | 2015 | Retro-spective | 4 | 2012-2014 | 4/0 | 45-66 | Alcoholic liver cirrhosis, trauma, body pain | Tusanqi (600-1500 g) | 1-4 mo | Clinical manifesta-tions + imaging |
| 5 | Ren et al[ | China | 2017 | Retro-spective | 239 | 2010-2017 | 151/88 | 15-86 (59.6 ± 10.9) | Trauma, hypertension, extravasated blood, URI | Tusanqi | UK | Biopsy (48), Clinical manifesta-tions + imaging |
| 6 | Geng et al[ | China | 2009 | Retro-spective | 4 | 2007-2008 | 1/3 | 42-72, 57 | / | Tusanqi | 12-60 d | Clinical manifesta-tions |
| 7 | Chen et al[ | China | 2012 | Retro-spective | 45 | 1998-2011 | 23/22 | 33-73, 57 | Trauma | Tusanqi | 2-16 wk | Biopsy (21) Clinical manifesta-tions + laboratory examina-tion + imaging (8) |
| 8 | Zhang et al[ | China | 2012 | Retro-spective | 15 | 2005-2011 | 12/3 | 42-65 | / | Tusanqi | 1-6 mo | Biopsy (6) DSA (1) Clinical manifesta-tions + laboratory examina-tion + MRI |
| 9 | Li | China | 2011 | Retro-spective | 4 | 2009-2011 | 2/2 | 27-63, 35 | / | Tusanqi (3), chemo-therapy (1) | Tusanqi (1-3 mo) | Biopsy (2) Clinical manifesta-tions + imaging |
| 10 | Hu et al[ | China | 2011 | Retro-spective | 5 | 2006-2011 | 4/1 | 40-60 | Trauma history (3), health fitness (1) | Tusanqi | ≥1 mo | Biopsy (2) Clinical manifesta-tions + imaging |
| 11 | Li et al[ | China | 2015 | Retro-spective | 4 | 2009-2014 | 3/1 | 35-61 | Myocar-dial infarction (1) | Tusanqi | / | UK |
| 12 | Li et al[ | China | 2014 | Retro-spective | 8 | 2011-2014 | 5/3 | 21-71, 44.9 | / | Tusanqi (2) Chemo-therapy or immune suppres-sive therapy (9) | / | Biopsy |
| 13 | Yu et al[ | China | 2013 | Retro-spective | 6 | 2002-2012 | 1/5 | 10-62 (36.5 ± 20.2) | Trauma (5) Irregular menstrua-tion (1) | Tusanqi (200-700 g) | 8-30 d | Biopsy |
| 14 | Rong[ | China | 2015 | Retro-spective | 51 | 2009-2015 | 36/15 | 20-79 | Drinking (14) Hyperten-sion (1) Diabetes (1) TB (1) RA (1) | Tusanqi (27) HSCT (4), | 3 d-4 yr | Biopsy (6) Clinical manifesta-tions + imaging |
| 15 | Pei et al[ | China | 2010 | Retro-spective | 6 | 2006-2008 | 2/4 | 17-46 | / | Tusanqi (5) | 30 d | Biopsy (3) Clinical manifesta-tions + imaging |
| 16 | Zhou et al[ | Hong Kong, China | 2014 | Retro-spective | 16 | 2009-2011 | 12/4 | 22-72, 55.6 | / | Intake of | UK | Liver transplanta-tion (1) Clinical manifesta-tions |
| 17 | Guo[ | China | 2015 | Retro-spective | 12 | 2013-2014 | 9/3 | 45-62, 53 | / | Tusanqi | UK | Clinical manifesta-tions + imaging |
| 18 | Yang[ | China | 2018 | Retro-spective | 39 | 2010-2016 | 9/30 | 36-74, 59.18 ± 9.36 | / | Pyrrolizi-dine alkaloid (PA)–containing herbals | UK | Clinical manifesta-tions + imaging |
UK: Unknown.
Clinical characteristics of 13 patients in 11 case reports, n (%)
| Sex (male/female) | 13 | 7/6 |
| Age, yr | 13 | 47.9 |
| None | 13 | 4 (30.8) |
| Postoperative liver metastasis of advanced colorectal cancer | 13 | 3 (23.1) |
| Leukemia | 13 | 2 (15.4) |
| Liver cirrhosis | 13 | 1 (7.7) |
| Hepatic metastasis of colonic carcinoma | 13 | 1 (7.7) |
| Gastric adenocarcinoma | 13 | 1 (7.7) |
| Ascites | 13 | 7 (53.8) |
| Abdominal swelling | 13 | 4 (30.8) |
| Pleural effusion | 13 | 4 (30.8) |
| Hepatomegaly | 13 | 3 (23.1) |
| Jaundice | 13 | 3 (23.1) |
| Stomach ache | 13 | 3 (23.1) |
| Weak | 13 | 3 (23.1) |
| Lower limbs edema | 13 | 2 (15.4) |
| Lower limbs lassitude | 13 | 2 (15.4) |
| Loss of appetite | 13 | 2 (15.4) |
| Yellow urine | 13 | 2 (15.4) |
| Oliguria | 13 | 1 (7.7) |
| Esophageal varices | 13 | 1 (7.7) |
| PVH | 13 | 1 (7.7) |
| Chemotherapy | 13 | 5 (38.5) |
| Tusanqi | 13 | 4 (30.8) |
| Hematopoietic stem cell transplantation | 13 | 2 (15.4) |
| “Poppers,” a recreational drug used during anal intercourse | 13 | 1 (7.7) |
| Drug toxicity (6-thioguanine) | 13 | 1 (7.7) |
| ALP, U/L | 11 | 206.4 |
| ALT, U/L | 9 | 836.2 |
| AST, U/L | 8 | 1284.25 |
| GGT, U/L | 7 | 155.42 |
| LDH, U/L | 3 | 5608.33 |
| TBil, μmol/L | 9 | 63.11 |
| DBil, μmol/L | 5 | 35 |
| Alb, g/L | 5 | 37.52 |
| TBA, g/L | 2 | 27.65 |
| T-CHE, U/L | 2 | 3242 |
| TP, g/L | 1 | 47.7 |
| CA-125, U/mL | 1 | 299.1 |
PVH: Portal hypertension; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transpeptidase; TBil: Total bilirubin; DBil: Direct bilirubin; prothrombin time; ALB: Albumin; TBA: Total bile acid.
Magnetic resonance imaging features of all 256 examinations, n (%)
| Heterogeneous signals on T1WI/T2WI | 221 (86.3) |
| Heterogeneous enhancement | 189 (73.8) |
| Ascites | 189 (73.8) |
| Hepatomegaly | 167 (65.2) |
| Narrowing and blurring of intrahepatic IVC | 167 (56.6) |
| Gallbladder wall edema | 121 (47.3) |
| Narrowing of three main hepatic veins | 105 (41.1) |
| Edema around the portal vein, "cuffing" | 90 (35.2) |
| Narrowing and blurring of intrahepatic veins | 52 (20.3) |
| Collateral circulation opens | 37 (14.6) |
| Splenomegaly | 32 (12.5) |
| Narrowing and blurring of portal vein | 28 (10.9) |
| Dilated and twisted small vessels | 17 (6.6) |
| Hypo-intensity on HBP | 17 (6.6) |
| Dilated hepatic arteries | 12 (4.7) |
| "Halo signs" around the hepatic vein and intrahepatic IVC | 11 (4.3) |
| Restricted diffusion | 5 (2.0) |
| Gastrointestinal edema | 4 (1.6) |
| Multiple hyperplasia nodules | 2 (0.8) |
| Caudate lobe enlargement | 2 (0.8) |
| Focal nodules or masses | 1 (0.4) |
| Dilated spleen vein | 1 (0.4) |
MRI: Magnetic resonance imaging; IVC: Inferior vena cava.